Previous close | 1.9100 |
Open | 1.9100 |
Bid | 1.7200 x 1800 |
Ask | 1.7500 x 1000 |
Day's range | 1.7300 - 1.9300 |
52-week range | 1.2100 - 3.0800 |
Volume | |
Avg. volume | 1,561,551 |
Market cap | 319.86M |
Beta (5Y monthly) | 1.31 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
CONCORD, Calif., May 02, 2024--Cerus Corporation (Nasdaq: CERS) today announced financial results for the first quarter ended March 31, 2024.
CONCORD, Calif., April 18, 2024--Cerus Corporation (Nasdaq: CERS) announced today that its first quarter 2024 financial results will be released on Thursday, May 2, 2024, after the close of the stock market. The Company will host a conference call and webcast at 4:30 P.M. ET that afternoon, during which management will discuss the Company’s financial results and provide a general business overview and outlook.
CONCORD, Calif., March 26, 2024--Cerus Corporation (Nasdaq: CERS) today announced that the U.S. Food and Drug Administration (FDA) has granted approval of 12-month shelf life for INTERCEPT Platelet Processing Sets, from the date of manufacture, effective immediately. This approval extends the set shelf life by six months from the existing six-month shelf life that took effect following a set component change last year. All INTERCEPT Platelet Processing Sets in both customer and Cerus inventories